Section 2.2: Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Why This Topic Matters for the PANCE

Chronic Obstructive Pulmonary Disease (COPD) is a high-yield pulmonary condition on the PANCE, testing the candidate's ability to distinguish between emphysematous and bronchitic phenotypes, interpret diagnostic spirometry, classify severity using the GOLD criteria, apply evidence-based maintenance regimens, and manage acute exacerbations. A critical PANCE focus is understanding the strict criteria for long-term oxygen therapy and the specific indications for antibiotics during an exacerbation.

Definitions and Pathophysiology

COPD is a common, preventable, and treatable progressive airway disease characterized by persistent, non-reversible airflow limitation. The disease is primarily caused by chronic exposure to noxious particles, most commonly tobacco smoke. It encompasses two main pathological phenotypes, which frequently coexist:

• Chronic Bronchitis (Airway Disease): Clinically defined as a productive cough for at least 3 months in each of 2 consecutive years. Pathologically, chronic exposure to tobacco smoke or irritants induces inflammatory cell recruitment (neutrophils, CD8+ T-lymphocytes, and macrophages). This chronic inflammation leads to hypertrophy of the submucosal mucus-secreting glands in the trachea and bronchi, which is quantified by a Reid Index > 0.5 (the ratio of the thickness of the mucous gland layer to the thickness of the wall between the epithelium and cartilage). There is also marked goblet cell hyperplasia in the small bronchioles, causing hypersecretion of thick mucus, mucosal edema, and smooth muscle bronchoconstriction, which narrows the airway lumen.
• Emphysema (Parenchymal Destruction): Anatomically defined as permanent, abnormal enlargement of the air spaces distal to the terminal bronchioles, accompanied by the destruction of alveolar walls without obvious fibrosis. The underlying mechanism is a protease-antiprotease imbalance. Tobacco smoke stimulates alveolar macrophages and neutrophils to release proteases (primarily neutrophil elastase), which enzymatically degrade the elastin that maintains the structural integrity of alveolar walls. Normally, this process is inhibited by the protease inhibitor alpha-1 antitrypsin (AAT).
  • Centrilobular (Centriacinar) Emphysema: Characterized by destruction of the proximal respiratory bronchioles, with sparing of the distal alveolar ducts and sacs. It is strongly associated with cigarette smoking and predominantly affects the upper lobes of the lungs.
  • Panacinar (Panacinar) Emphysema: Characterized by uniform destruction of the entire acinus. It is classically associated with alpha-1 antitrypsin deficiency and predominantly affects the lower lobes of the lungs.
  • Consequences of Emphysema: The loss of alveolar walls decreases the surface area available for gas exchange, and the loss of elastic tissue reduces radial traction, causing the small airways to collapse during expiration. This results in air trapping and lung hyperinflation.

Clinical Presentation

• "Pink Puffers" (Emphysema-Predominant): Typically thin, cachectic patients due to the high metabolic demand of hyperventilation. They present with severe dyspnea and minimal cough. On exam, they display a barrel chest (increased anteroposterior chest diameter), use accessory muscles, and breathe through pursed lips. Pursed-lip breathing increases airway pressure during expiration, preventing airway collapse. They are typically pink because they maintain relatively normal blood oxygen levels through hyperventilation.
• "Blue Bloaters" (Chronic Bronchitis-Predominant): Typically overweight and cyanotic due to chronic hypoxemia and hypercapnia. They present with a prominent, productive cough with purulent sputum. Chronic hypoxemia triggers pulmonary arterial vasoconstriction, leading to pulmonary hypertension, right ventricular hypertrophy, and cor pulmonale (right-sided heart failure). Physical signs include jugular venous distention (JVD), hepatomegaly, and bilateral lower extremity pitting edema.

Diagnostic Workup

• Spirometry: The diagnostic gold standard. It demonstrates a post-bronchodilator FEV1/FVC ratio < 0.70, confirming persistent airflow limitation. Unlike asthma, this obstruction is not fully reversible (FEV1 does not return to normal).
• GOLD Severity Classification: Graded by the post-bronchodilator FEV1 percentage of the predicted value in patients with FEV1/FVC < 0.70:
  1. GOLD 1 (Mild): FEV1 >= 80% predicted
  2. GOLD 2 (Moderate): 50% <= FEV1 < 80% predicted
  3. GOLD 3 (Severe): 30% <= FEV1 < 50% predicted
  4. GOLD 4 (Very Severe): FEV1 < 30% predicted
• Chest X-ray: Emphysema shows hyperinflation, flattened diaphragms, increased retrosternal airspace, and a long, narrow heart shadow. Chronic bronchitis shows increased bronchovascular markings ("dirty lungs").
• Alpha-1 Antitrypsin (AAT) Level: Screen all patients diagnosed with COPD under the age of 45, or non-smokers with lower lobe emphysema, or patients with a family history of AAT deficiency or early-onset emphysema.

Phenotypic Comparison

Clinical Management

Maintenance Pharmacological Therapy

The GOLD guidelines utilize the ABCD assessment tool based on symptom burden (mMRC dyspnea scale or CAT score) and exacerbation history:

• Group A (low symptoms, low risk): A single bronchodilator (short- or long-acting).
• Group B (high symptoms, low risk): A Long-Acting Muscarinic Antagonist (LAMA, e.g., tiotropium) or a Long-Acting Beta-Agonist (LABA, e.g., salmeterol). LAMA is preferred.
• Group C (low symptoms, high risk): A LAMA.
• Group D (high symptoms, high risk): LAMA + LABA combination. Consider adding an Inhaled Corticosteroid (ICS) if blood eosinophils are >= 300 cells/uL.

Mortality-Reducing Interventions

Only two interventions are proven to prolong survival in COPD patients:

1. Smoking Cessation: The most effective intervention to slow the rate of FEV1 decline.
2. Long-Term Oxygen Therapy (LTOT): Prescribed for patients who meet specific criteria:
   • Resting arterial oxygen tension (PaO2 <= 55 mmHg) or oxygen saturation (SaO2 <= 88%) on room air, OR
   • Resting PaO2 of 56-59 mmHg or SaO2 of 89% if accompanied by signs of cor pulmonale, pulmonary hypertension, or erythrocytosis (hematocrit > 55%).

Acute Exacerbation Management

Exacerbations are defined by an acute increase in dyspnea, sputum volume, or sputum purulence.

• Oxygen Therapy: Titrate supplemental oxygen to a target saturation of 88% to 92% (avoid over-oxygenating, which can suppress the hypoxic respiratory drive, worsen V/Q mismatch due to loss of hypoxic pulmonary vasoconstriction, and induce hypercapnia via the Haldane effect).
• Pharmacotherapy: Nebulized SABA (albuterol) and SAMA (ipratropium), systemic corticosteroids (prednisone 40 mg daily for 5 days), and empiric antibiotics (e.g., azithromycin, doxycycline, or levofloxacin).
• Antibiotic Indications: Indicated if the patient has all three cardinal symptoms (increased dyspnea, sputum volume, and sputum purulence), or two symptoms if one is increased purulence, or if they require mechanical ventilation.
• Non-invasive Positive Pressure Ventilation (BiPAP): Indicated for respiratory acidosis (pH < 7.35, PaCO2 > 45 mmHg) or severe respiratory distress.

Classic PANCE Traps and Clinical Pearls

• The Oxygen Trap: Do not target normal oxygen saturations (e.g., > 95%) in patients with chronic hypercapnic COPD. Doing so can cause hypoventilation and carbon dioxide retention, leading to CO2 narcosis and coma. Target 88-92%.
• Young Emphysema: A young patient (< 45 years) who presents with emphysema or a patient who is a non-smoker with lower lobe emphysema should immediately make you think of alpha-1 antitrypsin deficiency. They may also present with unexplained hepatitis or cirrhosis.